Evaluate the Efficacy and Safety of Reslizumab for Patients with Eosinophilic Asthma
Study Title
- A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma
Teva Identifier
- C38072/3081 | 2010-023342-67
ClinicalTrials.gov Identifier
- NCT01270464
Study Status
- Completed
Trial Condition(s)
- Eosinophilic Asthma
Interventions
- Drug: Reslizumab | Drug: Placebo
Study Description
- Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
Gender
- Female, Male
Age Range
- 12 Years to 75 Years
Trial Duration
- 02/01/2011 - 09/01/2013
Phase
- Phase 3
Study Type
Interventional
